📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines xiii/2024 { "detected_language": "romanian", "translated_text": "lot-0004, title: acyclovir type combinations 400 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0009, title: alprazolam type combinations 0.5mg, frontin 0.5mg, xanax 0.5mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0025, title: codeine phosphate lph 15 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0028, title: diazepam 10 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0029, title: refen 75 mg -25mg/ml-3ml type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0065, title: tavanic 250 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0071, title: advantan cream type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0072, title: advantan ointment type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0082, title: neostigmine lph 15 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0107, title: teotard 200 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0108, title: teotard 350 mg type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0118, title: tramadol retard 150 mg type combinations ®, mabron retard 150 mg or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities under both the framework agreement and the subsequent contract, as estimated value excluding vat: 1156126.40 ron.Centralized framework agreement for 24 months for the supply of medicines xiii/2024
